BACKGROUND: We compared new Aspergillus Galactomannan Lateral Flow Assay with the newly formatted Aspergillus-specific Lateral Flow device tests for the diagnosis of invasive pulmonary aspergillosis (IPA) in non-neutropenic patients. METHODS: We performed both tests in 82 bronchoalveolar lavage fluid samples from 82 patients at risk for IPA but without underlying haematologic malignancy. Samples were collected between September 2016 and September 2018 at the University of California San Diego, United States. IPA was classified following two published consensus criteria. RESULTS: Classification of cases varied widely between the two consensus criteria. When using criteria established for the intensive care unit, 26/82 patients (32%) met criteria for proven or putative IPA. Both point-of-care assays showed sensitivities ranging between 58% and 69%, with specificities between 68% and 75%. Sensitivity increased up to 81% when both tests were combined. CONCLUSION: The study outlines the need for updated, unified and more broadly applicable consensus definitions for classifying IPA in non-neutropenic patients, a work that is currently in progress. Both point-of-care tests showed comparable performance, with sensitivities and specificities in the 60%-70% range when used alone and increasing to 80% when used in combination. The new point-of-care tests may serve a role at the bedside in those with clinical suspicion of IPA.
BACKGROUND: We compared new AspergillusGalactomannan Lateral Flow Assay with the newly formatted Aspergillus-specific Lateral Flow device tests for the diagnosis of invasive pulmonary aspergillosis (IPA) in non-neutropenicpatients. METHODS: We performed both tests in 82 bronchoalveolar lavage fluid samples from 82 patients at risk for IPA but without underlying haematologic malignancy. Samples were collected between September 2016 and September 2018 at the University of California San Diego, United States. IPA was classified following two published consensus criteria. RESULTS: Classification of cases varied widely between the two consensus criteria. When using criteria established for the intensive care unit, 26/82 patients (32%) met criteria for proven or putative IPA. Both point-of-care assays showed sensitivities ranging between 58% and 69%, with specificities between 68% and 75%. Sensitivity increased up to 81% when both tests were combined. CONCLUSION: The study outlines the need for updated, unified and more broadly applicable consensus definitions for classifying IPA in non-neutropenicpatients, a work that is currently in progress. Both point-of-care tests showed comparable performance, with sensitivities and specificities in the 60%-70% range when used alone and increasing to 80% when used in combination. The new point-of-care tests may serve a role at the bedside in those with clinical suspicion of IPA.
Authors: Peter G Pappas; Barbara D Alexander; David R Andes; Susan Hadley; Carol A Kauffman; Alison Freifeld; Elias J Anaissie; Lisa M Brumble; Loreen Herwaldt; James Ito; Dimitrios P Kontoyiannis; G Marshall Lyon; Kieren A Marr; Vicki A Morrison; Benjamin J Park; Thomas F Patterson; Trish M Perl; Robert A Oster; Mindy G Schuster; Randall Walker; Thomas J Walsh; Kathleen A Wannemuehler; Tom M Chiller Journal: Clin Infect Dis Date: 2010-04-15 Impact factor: 9.079
Authors: A Cornillet; C Camus; S Nimubona; V Gandemer; P Tattevin; C Belleguic; S Chevrier; C Meunier; C Lebert; M Aupée; S Caulet-Maugendre; M Faucheux; B Lelong; E Leray; C Guiguen; J-P Gangneux Journal: Clin Infect Dis Date: 2006-07-27 Impact factor: 9.079
Authors: J Guinea; M Torres-Narbona; P Gijón; P Muñoz; F Pozo; T Peláez; J de Miguel; E Bouza Journal: Clin Microbiol Infect Date: 2009-11-10 Impact factor: 8.067
Authors: Wouter Meersseman; Katrien Lagrou; Johan Maertens; Alexander Wilmer; Greet Hermans; Steven Vanderschueren; Isabel Spriet; Eric Verbeken; Eric Van Wijngaerden Journal: Am J Respir Crit Care Med Date: 2007-09-20 Impact factor: 21.405
Authors: Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett Journal: Clin Infect Dis Date: 2008-06-15 Impact factor: 9.079
Authors: D Neofytos; D Horn; E Anaissie; W Steinbach; A Olyaei; J Fishman; M Pfaller; C Chang; K Webster; K Marr Journal: Clin Infect Dis Date: 2009-02-01 Impact factor: 9.079
Authors: C Cordonnier; F Botterel; R Ben Amor; C Pautas; S Maury; M Kuentz; Y Hicheri; S Bastuji-Garin; S Bretagne Journal: Clin Microbiol Infect Date: 2008-12-20 Impact factor: 8.067
Authors: A Arastehfar; A Carvalho; J Houbraken; L Lombardi; R Garcia-Rubio; J D Jenks; O Rivero-Menendez; R Aljohani; I D Jacobsen; J Berman; N Osherov; M T Hedayati; M Ilkit; D James-Armstrong; T Gabaldón; J Meletiadis; M Kostrzewa; W Pan; C Lass-Flörl; D S Perlin; M Hoenigl Journal: Stud Mycol Date: 2021-05-10 Impact factor: 16.097
Authors: Matthias Egger; Samuel Penziner; Karl Dichtl; Max Gornicec; Lisa Kriegl; Robert Krause; Ethan Khong; Sanjay Mehta; Milenka Vargas; Sara Gianella; Magali Porrachia; Jeffrey D Jenks; Iswariya Venkataraman; Martin Hoenigl Journal: J Clin Microbiol Date: 2022-03-30 Impact factor: 11.677
Authors: Amir Arastehfar; Agostinho Carvalho; Frank L van de Veerdonk; Jeffrey D Jenks; Philipp Koehler; Robert Krause; Oliver A Cornely; David S Perlin; Cornelia Lass-Flörl; Martin Hoenigl Journal: J Fungi (Basel) Date: 2020-06-24
Authors: Stephen A Rawlings; Sven Heldt; Juergen Prattes; Susanne Eigl; Jeffrey D Jenks; Holger Flick; Jasmin Rabensteiner; Florian Prüller; Albert Wölfler; Peter Neumeister; Heimo Strohmaier; Robert Krause; Martin Hoenigl Journal: Front Immunol Date: 2019-08-02 Impact factor: 7.561